Biological Age Biomarker Panels — Predictive Validity for Age-Related Decline

The claim is partially supported and fragmenting. Blood-based biomarker panels demonstrate population-level predictive validity for biological aging outcomes — at the population level, high biological age scores predict faster subsequent decline, higher mortality risk, and earlier disease onset. This is well-established across multiple panel types (epigenetic, proteomic, metabolomic) and multiple longitudinal cohorts. The population-level claim is supported. The claim fragments at the individual level. Different biological age clocks give substantially different estimates for the same individual, and organ systems within one person age at markedly different rates (INST-003): a blood panel captures a composite population-level signal that may not reflect which specific organ or process is declining fastest in any given person. The pressure state is FRAGMENTING: population-level predictive validity is well established, but individual-level predictive validity — the form the claim requires for clinical use — has not been demonstrated, and the actionability gap identified in DunedinPACE (INST-004) means that even a valid individual-level signal may not yet translate into a clear intervention (BN-001).